We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reversal of New Onset Type 1 Diabetes by Oral Salmonella -Based Combination Therapy and Mediated by Regulatory T-Cells in NOD Mice.
- Authors
Mbongue, Jacques C.; Rawson, Jeffrey; Garcia, Pablo A.; Gonzalez, Nelson; Cobb, Jacob; Kandeel, Fouad; Ferreri, Kevin; Husseiny, Mohamed I.
- Abstract
Autoimmune diseases such as type 1 diabetes (T1D) involve the loss of regulatory mechanisms resulting in increased tissue-specific cytotoxicity. The result is destruction of pancreatic insulin-producing β-cells and loss of glucose homeostasis. We are developing a novel oral vaccine using live attenuated Salmonella to deliver TGFβ, IL10, and the diabetic autoantigen preproinsulin combined with low-doses of anti-CD3 mAb. Here we show that oral administration of Salmonella -based anti-CD3 mAb combined therapy reverses new-onset T1D in non-obese diabetic (NOD) mice. The therapeutic effect of the combined therapy was associated with induction of immune suppressive CD4+CD25+Foxp3+ Treg and CD4+CD49b+LAG3+ Tr1 cells. In adoptive transfer experiments, adding or depleting Treg or Tr1 cells indicated that both are important for preventing diabetes in combined therapy-treated mice, but that Tr1 cells may have a more central role. Furthermore, induced Tr1 cells were found to be antigen-specific responding to peptide stimulation by secreting tolerance inducing IL10. These preclinical data demonstrate a role for Treg and Tr1 cells in combined therapy-mediated induction of tolerance in NOD mice. These results also demonstrate the potential of oral Salmonella -based combined therapy in the treatment of early T1D.
- Subjects
TYPE 1 diabetes; SALMONELLA; T cells; AUTOIMMUNE diseases; CD4 antigen; PEPTIDES
- Publication
Frontiers in Immunology, 2019, pN.PAG
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2019.00320